Can Gilead make remdesivir pay?
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
Long term forecasts confirm Keytruda’s dominance
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Covid-19 adds a new danger to drug launches
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
New Covid-19 test and a decent first quarter buoy Abbott
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
Esperion shifts to show not tell
After spending years insisting that its cholesterol-lowering medicine has a place between statins and PCSK9 inhibitors, Esperion must now prove it.
Sanofi's geriatric pipeline fails to freshen up
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
